Skip to main content

Table 6 Application of the proposed spectroscopic methods for the determination of OLO in pharmaceutical dosage forms

From: Determination of antihistaminic drugs alcaftadine and olopatadine hydrochloride via ion-pairing with eosin Y as a spectrofluorimetric and spectrophotometric probe: application to dosage forms

Dosage form

% Recovery ± SDa

 

Reported method [9]

Method C

Method D

Olohistine® 0.1%

100.35 ± 0.67

100.05 ± 0.60

(t = 0.74, F = 1.23)

100.12 ± 0.64 (t = 0.56, F = 1.10)

Conjyclear forte® 0.2%

100.45 ± 0.63

100.23 ± 0.74

(t = 0.83, F = 1.54)

101.25 ± 0.98

(t = 1.54, F = 2.44)

Conjyclear forte® 0.2% SDU

100.02 ± 0.61

99.66 ± 0.76

(t = 0.50, F = 1.93)

99.48 ± 0.99

(t = 1.04, F = 2.61)

  1. aNumber of determinations = 5
  2. bTabulated value at 95% confidence limit; t = 2.306 and F = 6.338
Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us